However, although PD-1/PDL-1 drugs have shown the potential therapeutic benefits, toxicity and high financial costs should be considered together with the fact that robust evidence from randomized clinical trials is still insufficient [76], although nivolumab has received FDA approval for the adjuvant treatment of patients with urothelial carcinoma at a high risk of recurrence following radical resection regardless of prior treatment with neoadjuvant chemotherapy, nodal involvement, or PD-L1 status [77]. Here, CD274 is linked to urothelial carcinoma.